Drug intelligence / Profile preview

ONC-005

Development stage: Preclinical
Lead developer: RapaFusyn Pharmaceuticals
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

ONC-005 is an early-stage oncology drug candidate being developed by RapaFusyn Pharmaceuticals for the treatment of solid tumors. It is part of the company's RapaGlues™ platform, which focuses on the discovery of rapamycin-based macrocycles that function as molecular glues. These molecules are designed to induce or stabilize protein-protein interactions, potentially leading to the degradation of target proteins (molecular glue degraders) or modulating their function without degradation. As of the current pipeline status, ONC-005 is in the Hit Identification to Hit to Lead stage of preclinical development.

Targets

FKBP1A

Beyond the preview

Go deeper on ONC-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONC-005.

Explore the full profile